[Editorial] New interventions offer prostate cancer hope

Prostate cancer is one of the most common cancers worldwide, with about 1·1 million cases diagnosed annually. Depending on the stage of disease at diagnosis, prostate cancer can be managed with combinations of active surveillance, surgery, radiotherapy, and androgen-deprivation therapy (ADT). However, some men have aggressive disease, in which rising concentrations of prostate-specific antigen (PSA) herald biochemical relapse and metastatic disease, even after treatment. Currently, no standard treatment is available for these men; however, promising new data from two trials presented at the 2018 ASCO Genitourinary Cancers Symposium (Feb 8–10, 2018, San Francisco, CA, USA) suggest that this situation might be about to change.

https://ift.tt/2pPcZZ9